Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2011 Jan;18(1):239-45.
doi: 10.1245/s10434-010-1242-6. Epub 2010 Aug 10.

Supratentorial glioblastoma multiforme: the role of surgical resection versus biopsy among older patients

Kaisorn L Chaichana  1 , Tomas Garzon-Muvdi, Scott Parker, Jon D Weingart, Alessandro Olivi, Richard Bennett, Henry Brem, Alfredo Quiñones-Hinojosa
Affiliations
Clinical Trial

Supratentorial glioblastoma multiforme: the role of surgical resection versus biopsy among older patients

Kaisorn L Chaichana et al. Ann Surg Oncol. 2011 Jan.

Abstract

Background: The peak incidence of glioblastoma multiforme (GBM) occurs in those aged 65 years and older. However, studies on this patient group remain limited. The goal of this study is to evaluate the efficacy of surgery versus biopsy for older patients with these lesions.

Methods: 133 and 72 consecutive patients aged 65 years and older who underwent surgery and needle biopsy for intracranial primary (de novo) GBM between 1997 and 2007 were retrospectively reviewed. Among these patients, 40 who underwent surgical resection were matched with 40 who underwent needle biopsy alone for factors consistently shown to be associated with survival [age, Karnofsky Performance Scale (KPS) indexing, eloquent involvement, radiation, temozolomide]. Survival was expressed as estimated Kaplan-Meier plots, and log-rank analysis was used to compare survival curves.

Results: Mean ± standard deviation age was 73 ± 5 years, and median survival was 4.9 months. There were no significant differences in perioperative outcomes among patients who underwent surgical resection versus needle biopsy. Patients who underwent resection had median survival of 5.7 months as compared with 4.0 months for patients who underwent needle biopsy (P = 0.02). Likewise, for patients aged 70 years and older, median survival was 4.5 months for 26 patients who underwent surgical resection as compared with 3.0 months for 26 patients who underwent needle biopsy (P = 0.03).

Conclusion: This study demonstrates that older patients tolerate aggressive surgery without increased surgery-related morbidity and have prolonged survival as compared with similar patients undergoing needle biopsy. These findings may help guide treatment decisions for patients, their families, and their physicians.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Kaplan–Meier plots of survival for older patients (aged 65 years and older) with glioblastoma multiforme (GBM) who underwent surgical resection or needle biopsy. Median survival was 4.9 months, and 3-, 6-, 9-, and 12-month survival rates were 63%, 33%, 21%, and 14%, respectively
Fig. 2
Fig. 2
Kaplan–Meier plots of survival for older patients (aged 65 years and older) who underwent surgical resection versus biopsy of a primary glioblastoma multiforme (GBM). Median survival was significantly longer for patients who underwent aggressive resection as compared with patients who underwent biopsy (5.7 versus 4.0 months, respectively, P = 0.02). The groups were matched for age, Karnofsky performance score (KPS index), eloquent location, postoperative radiation, and postoperative temozolomide chemotherapy
Fig. 3
Fig. 3
Kaplan–Meier plots of survival for older patients (aged 70 years and older) who underwent surgical resection versus biopsy of a primary glioblastoma multiforme (GBM). Median survival was significantly longer for patients who underwent surgical resection as compared with needle biopsy (4.5 versus 3.0 months, respectively, P = 0.03). The groups were matched for age, Karnofsky performance score (KPS), eloquent location, postoperative radiation, and postoperative temozolomide chemotherapy
See this image and copyright information in PMC

References

    1. Wrensch M, Minn Y, Chew T, Bondy M, Berger MS. Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol. 2002;4:278–99. - PMC - PubMed
    1. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;10:997–1003. - PubMed
    1. Barnholtz-Sloan JS, Williams VL, Maldonado JL, Shahani D, Stockwell HG, Chamberlain M, et al. Patterns of care and outcomes among elderly individuals with primary malignant astrocytoma. J Neurosurg. 2008;4:642–8. - PubMed
    1. Iwamoto FM, Cooper AR, Reiner AS, Nayak L, Abrey LE. Glioblastoma in the elderly: the Memorial Sloan–Kettering Cancer Center experience (1997–2007) Cancer. 2009;16:3758–66. - PMC - PubMed
    1. Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet. 1995;8956:1008–12. - PubMed

Publication types